Email bulletins

Archive

August 2017

• World Hepatitis Day: steps towards elimination
• Drug prices: time to shift from talking about high prices to low production costs
• Hepatitis C: DAA treatment and mortality
• Vosevi approved in the European Union and United States
• Maviret approved in the European Union and United States
• Epclusa use expanded to people with HIV co-infection in the United States
• Harvoni licence extended to adolescents aged 12-18 years in European Union
• Hepatitis C treatment in Africa
• Non-alcoholic fatty liver disease in people living with HIV
• Is this your copy of the infohep news bulletin?

June 2017

• Cochrane review of hepatitis C treatment strongly criticised
• New pangenotypic drug combinations
• Recent infection with hepatitis C and testing for hepatitis C
• Sofosbuvir treatment for adolescents and children
• US monitoring and surveillance recommendations
• Coming soon: IAS 2017
• Is this your copy of the infohep news bulletin?

May 2017

• New hepatitis C infections in the United States
• HCV reinfection among people who inject drugs
• Gilead warning on generics – weeks after more evidence on effectiveness
• Albumin treatment in decompensated cirrhosis
• New drugs for hepatitis B treatment
• Is this your copy of the infohep news bulletin?

April 2017

• News from the 2017 International Liver Congress
• WHO Global Hepatitis Report 2017
• New hepatitis B clinical guidelines from EASL
• HCV reimbursement criteria in Europe
• Direct-acting antivirals and liver cancer risk
• Hepatitis C treatment for children
• AbbVie combination
• HCV treatment reduces cardiovascular risk
• Parkinson’s disease and hepatitis
• Statins reduce the risk of decompensation
• Antibiotic prophylaxis reduces mortality in decompensated cirrhosis
• Coming soon: HR17
• Is this your copy of the infohep news bulletin?

April 2017

• Progress towards elimination of hepatitis C
• Global Burden of Disease study shows viral hepatitis causes more deaths than HIV or TB
• Debate: Not all drug preparation equipment may contain infectious HCV
• Women who inject drugs at greater risk of HCV
• Nivolumab (Opdivo) approved for hepatocellular carcinoma treatment in the United States
• Janssen halts hepatitis C drug research
• Next month: news coverage of The Liver Meeting 2017
• Is this your copy of the infohep news bulletin?

March 2017

• Early treatment for hepatitis C
• Access to hepatitis C treatment in South East Asia
• Cancers
• Liver cancer and treatment for viral hepatitis
• Direct-acting antiviral treatment achieves high cure rates in the most advanced liver disease patients with HIV co-infection
• Glecaprevir/pibrentasvir combination does not interact with HIV medications
• Hepatitis A outbreak in Europe
• Hepatitis C community summit, 18 & 19 April, Amsterdam
• Is this your copy of the infohep news bulletin?

February 2017

• HCV treatment as prevention
• Progress towards HCV elimination
• Guidelines on HCV and HBV testing
• Effects of hepatitis C cure on extrahepatic disease in people with HIV/HCV co-infection
• Lonafarnib for hepatitis delta
• Is this your copy of the infohep news bulletin?

January 2017

• Hep-CORE
• Direct-acting antiviral treatment and kidney disease
• Liver transplant demand
• Liver cancer treatment
• Vemlidy for hepatitis B approved in European Union
• Counterfeit Harvoni found in Japan
• Is this your copy of the infohep news bulletin?